Stranica je namijenjena samo zdravstvenim radnicima u Republici Hrvatskoj.

Search

Menu

Close

PrijavaOdjava
Naši lijekoviTerapijska područjaMedia CentarMedia CentarDogađanjaMaterijaliVideo resursiKontaktirajte nasPovežimo seKontaktirajte nasMedicinske informacije tvrtke Pfizer

Informacije o prijavljivanju nuspojava mogu se pronaći na dnu stranice.

Menu

Close

About Prevenar 20™ at a Glance Serotype Coverage Pneumococcal Disease Clinical Programme RecommendationsPractical Use Resources
Deliver the broadest serotype coverage for babies1-3Prevenar 20™ helps protect against the 20 Streptococcus pneumoniae serotypes in the vaccine1
Discover expanded serotype coverage
Loading Recommended by [Local body] for healthy babies, preterm infants, and children at increased risk for invasive pneumococcal disease1,6 Learn more Loading Demonstrated robust immune response against 20 serotypes after [__] doses with a safety profile comparable to Prevenar 13®1 Review trial results LoadingReferences:References:Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2024.Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2014.Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine). Summary of Product Characteristics. Merck Sharp & Dohme Corp.; 2023.Prevenar® (Pneumococcal 7-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2011.van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imöhl M. Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. PLoS One. 2016;11(8):e0161257.Centers for Disease Control and Prevention. ACIP updates: recommendations for the use of 20-valent pneumococcal conjugate vaccine in children—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(39):1072. https://stacks.cdc.gov/view/cdc/133252.Local approval dates.
PP-PNR-GLB-0425 March 2024

Ako želite prijaviti štetni događaj, molimo Vas pošaljite e-mail na adresu [email protected] ili nazovite broj 013908788. Za medicinske upite, molimo Vas pošaljite e-mail na adresu: [email protected] ili nazovite broj 013908777.

PfizerPro računPfizerPro račun

Za pristup daljnjim materijalima, resursima i primanje obavijesti o lijekovima i cjepivima tvrtke Pfizer

PrijavaRegistracijaRačunOdjava

SAMO ZA ZDRAVSTVENE RADNIKE

Stranica je namijenjena samo zdravstvenim radnicima u Republici Hrvatskoj. Ako ste član šire javnosti koji želi ostvariti pristup informacijama o određenom lijeku, molimo Vas obratite se Vašem liječniku ili ljekarniku. 

Ovu web stranicu Vam donosi Pfizer Croatia d.o.o.

Autorsko pravo 2022. Pfizer Croatia d.o.o. Sva prava pridržana.

PP-UNP-HRV-0139, datum izrade: kolovoz, 2023.
Napuštate PfizerPro
​
Sada napuštate internetsku stranicu kojom upravlja Pfizer. Poveznice koje vode svim vanjskim stranicama su dani kao resurs za naše posjetitelje. Pfizer ne prihvaća nikakvu odgovornost za sadržaj stranica koji nisu u vlasništvu i kojima Pfizer ne upravlja.

PP-UNP-HRV-0139
datum izrade: kolovoz, 2023.
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​ Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​